Summary
Total cytosolic cathepsin D (Cat D) levels were estimated by an immunoradiometric assay in a series of 156 consecutive patients with surgical stages I–III primary endometrial adenocarcinoma. Simultaneously, the tissue content of both oestrogen (ER) and progesterone (PR) receptors, and p185HER-2/neu, DNA content (ploidy), and the fraction of S-phase cells (S-phase) were also estimated. Tumoral Cat D content ranged from 0 to 243 pmol mg–1 protein (median 44 pmol mg–1 protein) and was not associated with any of the established clinicopathological and biological prognostic variables, with the exception of a weak positive correlation with the tumoral p185HER-2/neu levels. Univariable analysis performed on a subset of 97 patients, followed for a minimum of 2 years or until death, showed that patient age at diagnosis, high histological grade, advanced surgical stage, vascular invasion, positive peritoneal cytology, low levels of Cat D, negative ER and PR status, aneuploidy, and high S-phase were predictive of the presence of persistent or recurrent disease. However, multivariable analysis revealed that only histological grade, surgical stage, Cat D and PR were significantly associated with the patient’s outcome. From these findings, we conclude that Cat D is an independent prognostic factor in endometrial adenocarcinoma, its low levels being associated with a worse clinical outcome.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Altman, D. G., Lausen, B., Sauerbrei, W. & Schumacher, M. (1994). Dangers of using “optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829–835.
Barakat, R. R., Park, R. C., Grigsby, P. W., Muss, H. D. & Norris, H. (1997). Corpus: epithelial tumors. In Principles and Practice of Gynecologic Oncology, 2nd edn Hoskins WJ, Perez CA and Young RC (eds.), pp. 859–896, Lippincott-Raven: Philadelphia
Benraad, T. H. J., Geurts-Moespot, A., Sala, M., Piffanelli, A., Ross, A. & Foekens, J. A. (1992). Quality control of cathepsin D measurement by the EORTC Receptor Study Group. Eur J Cancer 28A: 72–75.
Capony, F., Garcia, J., Capdevielle, C., Rougeot, C., Ferrara, P. & Rochefort, H. (1986). Purification and first characterization of the secreted and cellular 52-kDa proteins regulated by estrogens in human breast cancer cells. Eur J Biochem 161: 505–512.
Capony, F., Rougeot, C., Montcourrier, P., Cavailles, V., Salazar, G. & Rochefort, H. (1989). Increased secretion, altered processing, and glycosilation of procathepsin D in human mammary cancer cells. Cancer Res 46: 3904–3909.
Christopherson, W. M., Connelly, P. J. & Alberhasky, R. C. (1983). An analysis of prognosticators in patients with favorable subtypes and stage I disease. Cancer 51: 1705–1709.
Creasman, W. T. (1993). Prognostic significance of hormone receptors in endometrial cancer. Cancer 71: 1467–1470.
Creasman, W. T., Morrow, P. C., Bundy, B. N., Homesley, H. D., Graham, J. E. & Heller, P. B. (1987). Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group Study. Cancer 60: 2035–2041.
Elangovan, S. & Moulton, B. C. (1980). Progesterone and estrogen control of rates of synthesis of uterine cathepsin D. J Biol Chem 255: 7474–7479.
Ferrandina, G., Scambia, G., Bardelli, F., Benedetti Panici, P., Mancuso, S. & Messori, A. (1997). Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer 76: 661–666.
Foekens, J. A., van Putten, W. L. J., Portengen, H., de Koning, HYWCM, Thirion, B., Alexieva-Figusch, J. & Klijn, J. G. M. (1993). Prognostic value of pS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J Clin Oncol 11: 899–908.
Gion, M., Mione, R., Dittadi, R., Romanelli, M., Pappagallo, L., Capitanio, G., Friede, U., Barbazza, R., Visonà, A. & Dante, S. (1995). Relationship between cathepsin D and other pathological and biological parameters in 1752 patients with primary breast cancer. Eur J Cancer 31A: 671–677.
Henry, J. A., McCarthy, A. L., Angus, B., Westley, B. R., May, F. E. B., Nicholson, S., Cairns, J., Harris, A. L. & Horne, C. H. W. (1990). Prognostic significance of the oestrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer 15: 265–271.
Hetzel, D. J., Wilson, T. O., Keeney, G. L., Roche, P. C., Cha, S. S. & Podratz, K. C. (1992). HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 47: 179–185.
Isola, J., Weitz, S., Visakorpi, T., Holli, K., Shea, R., Khabbez, N. & Kallioniemi, O. P. (1993). Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breat cancer. J Clin Oncol 11: 36–43.
Lösch, A., Kohlberger, P., Gitsch, G., Kaider, A., Breitnecker, G. & Kainz, C. H. (1996). Lysosomal protease cathepsin D is a prognostic marker in endometrial cancer. Br J Cancer 73: 1525–1528.
Lotocki, R. J., Copeland, L. J., DePetrillo, A. D. & Muirhead, W. (1983). Stage I endometrial adenocarcinoma: treatment results in 835 patients. Am J Obstet Gynecol 146: 141–144.
Lukes, A. S., Kohler, M. F., Pieper, C. F., Kerns, B. J., Bentley, R., Rodriguez, G. C., Soper, J. T., Clarke-Pearson, D. L., Bast, R. C. & Berchuck, A. (1994). Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 73: 2380–2385.
Malkasian, G. D., Annegars, J. F. & Fountain, K. S. (1980). Carcinoma of the endometrium: stage 1. Am J Obstet Gynecol 136: 872–888.
Marsigliante, S., Biscozzo, L., Correale, M., Paradiso, A., Leo, G., Abbate, I., Dragone, C. D. & Storelli, C. (1994). Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors. Br J Cancer 69: 550–554.
Mathieu, M., Rochefort, H., Barenton, B., Prebois, C. & Vignon, F. (1990). Interaction of the cathepsin D and IGF-II on the M6P/IGF-II receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-II. Mol Endocrinol 4: 1327–1335.
Maudelonde, T., Martinez, P., Brouillet, J. P., Laffargue, F., Pages, A. & Rochefort, H. (1990). Cathepsin-D in human endometrium: induction by progesterone and potential value as a tumor marker. J Clin Endocrinol Metab 70: 115–121.
Morisset, M., Capony, F. & Rochefort, H. (1986). The 52 kDa estrogen-induced protein secreted by MCF7 cells is a lysosomal acidic protease. Biochem Biophys Res Commun 138: 102–109.
Morrow, C. P., Bundy, B. N., Kurman, R. J., Creasman, W. T., Heller, P., Homesley, H. D. & Graham, J. E. (1991). Relationship between surgical–pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium. Gynecol Oncol 40: 55–65.
Nazeer, T., Malfetano, J. H., Rosano, T. G. & Ross, J. S. (1992). Correlation of tumor cytosol cathepsin D with differentiation and invasiveness of endometrial adenocarcinoma. J Clin Pathol 97: 764–769.
Nazeer, T., Church, K., Amato, C., Rosano, T. G., Malfetano, J. H. & Ross, J. S. (1994). Comparative quantitative inmunohistochemical and immunoradiometric determinations of cathepsin D in endometrial adenocarcinoma: predictors of tumor agressiveness. Mod Pathol 7: 469–474.
Newbury, R., Schuerch, C., Goodspeed, N., Fanning, J., Glidewell, O. & Evans, M. (1990). DNA content as a prognostic factor in endometrial carcinoma. Obstet Gynecol 76: 251–257.
Ravdin, P. M., Tandon, A. K., Allred, D. C., Clark, G. M., Fuqua, S. A. W., Hilsenbeck, S. H., Chamness, G. C. & Osborne, C. K. (1994). Cathepsin D by Western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 12: 467–474.
Ravdin, P. M., de Moor, C. A., Hilsenbeck, S. G., Samoszuk, M. K., Vendely, P. M. & Clark, G. M. (1997). Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients. Cancer Lett 116: 177–183.
Rochefort, H., Capony, F. & Garcia, M. (1990). Cathepsin D in breast cancer: from molecular and cellular biology to clinical applications. Cancer Cells 2: 383–387.
Roger, P., Montcourrier, P., Maudelonde, T., Brouillet, J. P., Pages, A., Laffargue, F. & Rochefort, H. (1994). Cathepsin D immunostaining in paraffin-embedded breast cancer cells and macrophages: correlation with cytosolic assay. Hum Pathol 25: 863–871.
Rosenberg, P., Wingren, S., Simonsen, E., Stal, O., Risberg, B. & Nordenskjold, B. (1989). Flow cytometric measurements of DNA index and S-phase on paraffin embedded early stage endometrial cancer: an important prognostic indicator. Gynecol Oncol 35: 50–54.
Sanfilippo, J. S., Miseljic, S., Yang, A. R., Doering, D. L. & Shaheen, R. M., Wittliff (1996). Quantitative analyses of epidermal growth factor receptors, HER-2/neu oncoprotein and cathepsin D in nonmalignant and malignant uteri. Cancer 77: 710–716.
Scambia, G., Benedetti Panici, P., Ferrandina, G., Distefano, M., Romanini, M. E., Sica, G. & Mancuso, S. (1995). Significance of cathepsin-D expression in uterine tumors. Eur J Cancer 31A: 1449–1454.
Seshadri, R., Horsfall, D. J., Firgaira, F., McCaul, K., Setlur, V., Chalmers, A. H., Yeo, R., Ingram, D., Dawkins, H. & Hahnel, R., the South Australian Breast Cancer Study Group (1994). The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in breast cancer. Int J Cancer 56: 61–65.
Spyratos, F., Brouillet, J. P., Defrenne, A., Hacene, K., Rouesse, J., Maudelonde, T., Brunet, M., Andrieu, C., Desplaces, A. & Rochefort, H. (1989). Cathepsin D: and independent prognostic factor for metastasis of breast cancer. Lancet 2: 1115–1118.
Tandon, A. K., Clark, G. M., Chamness, G. C., Chirgwin, J. M. & McGuire, W. L. (1990). Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297–302.
Thorpe, S., Rochefort, H. & Garcia, M. (1989). Association between high concentration of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49: 6008–6014.
Touitou, I., Cavailles, V., Garcia, M., Defrenne, A. & Rochefort, H. (1989). Differential regulation of cathepsin D by sex steroid in mammary cancer and uterine cells. Mol Cell Endocrinol 66: 231–238.
Valerón, P. F., Chirino, R., Fernández, L., Torres, S., Navarro, D., Aguiar, J., Cabrera, J. J., Díaz-Chico, B. N. & Díaz-Chico, J. C. (1996). Validation of a differential PCR and an ELISA procedure in studying HER-2/neu status in breast cancer. Int J Cancer 65: 129–133.
Valerón, P. F., Chirino, R., Vega, V., Falcón, O., Rivero, J. F., Torres, S., León, L., Fernández, L., Pestano, J., Díaz-Chico, B. N. & Díaz-Chico, J. C. (1997). Quantitative analysis of p185HER-2/neu protein in breast cancer and its association with other prognostic factors. Int J Cancer 74: 175–179.
Vindelov, L. & Christensen, I. J. (1990). An integrated set of methods for routine flow cytometric DNA analysis. Methods Cell Biol 33: 127–137.
Westley, B. & Rochefort, H. (1980). A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 20: 352–362.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Falcón, O., Chirino, R., León, L. et al. Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer. Br J Cancer 79, 570–576 (1999). https://doi.org/10.1038/sj.bjc.6690090
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690090